Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-681323 in Subjects at Risk for ALI or ARDS
NCT00996840Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dilmapimod in acute lung injury (ALI), acute respiratory distress syndrome (ARDS), sponsored by GSK. Started Oct 2009; status: completed.
02
Drugs
dilmapimod
03
Conditions
acute lung injury (ALI)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT00996840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00996840.